Hovione and H&T Presspart Extend Partnership for Dry Powder Inhalation Formulation Delivery
Presspart will still be responsible for the manufacturing of the Sunriser device.
Hovione and H&T Presspart have partnered to advance the development of Presspart’s Sunriser Capsule-based Dry Powder Inhaler platform. The companies plan to work together to develop the Sunriser Dry Powder Inhaler, which is flexible enough to address the challenges of carrier-based and spray-dried engineered formulations, according to the press release.
A part of the development agreement finds Hovione being an exclusive partner with Presspart to use the Sunriser device in engineered formulations for dry powder inhalation. Additionally, Presspart will still be responsible for the manufacturing of the Sunriser device.
"New inhalable therapies are often requiring delivery of higher doses of cohesive and sensitive powders. Our priority is to ensure maximum efficiency in delivering these drugs to the right locations in the lung,” said Jean-Luc Herbeaux, PhD, CEO of Hovione, in a press release. “We are thrilled to expand our current partnership with Presspart and combine our expertise in the fields of engineered particles and inhalers for the benefit of our customers and patients.”
Source: Hovione
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
